On Wednesday, the Food and Drug Administration issued a warning, calling compounded GLP-1 medications "risky for patients." "FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) receptor agonists) drugs, including semaglutide and tirzepatide, as an option for weight loss," the FDA said
The third hormone, glucagon, is what makes retatrutide different
That constant nausea on day three after the injection might mean that your dose is too high
Additionally, the FDA has issued warnings about ileus (bowel obstruction) after receiving 90 postmarketing reports
Tesamorelin , by contrast, is a synthetic analogue of growth hormone-releasing hormone (GHRH)